The C17orf75 Knockout HAP1 Polyclonal Cells product comprises a population of HAP1 cells that have been modified by CRISPR/Cas9-mediated gene disruption to introduce a loss-of-function mutation in the C17orf75 gene. This polyclonal knockout cell pool contains a heterogeneous mixture of edited alleles, providing a robust model for studying the functional consequences of C17orf75 deficiency. As a pooled knockout population, it avoids clonal selection and captures the diversity of editing outcomes, making it suitable for population-based assays and screens that require representing a broad spectrum of genetic modifications.
HAP1 is a near-haploid human cell line originally derived from the KBM-7 chronic myeloid leukemia cell line. Its haploid karyotype simplifies genetic manipulation and knockout validation because only a single allele needs to be disrupted to achieve functional loss of the target gene. HAP1 cells are widely employed in functional genomics, CRISPR-based screens, and knockout studies due to their ease of culture and the ability to perform high-throughput phenotypic analyses. The chronic myeloid leukemia origin of HAP1 cells also provides a context for studying cancer-related pathways, although the primary utility lies in its haploid nature.
C17orf75 is an uncharacterized open reading frame on chromosome 17, and its biological function remains largely unknown. No definitive molecular interactions, upstream regulators, downstream targets, or associated signaling pathways have been identified for the C17orf75 protein. The absence of characterized functional domains or homologs in model organisms adds to the challenge of predicting its role. Knockout of this gene in HAP1 cells provides a foundational tool for functional characterization studies aimed at elucidating its cellular function, including potential roles in proliferation, survival, or differentiation.
The haploid background of HAP1 cells offers a distinct advantage for studying uncharacterized genes such as C17orf75, as disruption of the single allele can immediately reveal loss-of-function phenotypes without the confounding effects of a second intact allele. The polyclonal nature of this knockout product further enhances robustness by minimizing clonal variability that can arise from single-cell-derived lines. This model is therefore well-suited for initial exploratory screens where rapid assessment of knockout phenotypes can guide more detailed mechanistic investigations. It enables researchers to bypass the time-consuming process of generating clonal lines while still obtaining biologically relevant insights.
Applications of these C17orf75 Knockout HAP1 Polyclonal Cells span multiple areas of basic and translational research. They can be used in functional genomics screens to identify phenotypic consequences of C17orf75 loss, in pooled CRISPR dropout screens to assess cellular fitness, and in complementation assays with wild-type or mutant C17orf75 constructs. Representative assays include RT-qPCR for verifying transcript loss, western blotting for protein absence (if antibodies are available), DNA sequencing to confirm editing at the target locus, and various functional assays such as proliferation, apoptosis, or cell cycle analysis. This knockout model serves as a versatile platform for the de-orphanization of C17orf75. For further information or technical support, please contact Ascent Research.
